Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)

PURPOSE: Approximately 10% to 15% of triple-negative breast cancers (TNBC) have deleterious mutations in BRCA1 and BRCA2 and may benefit from PARP inhibitor treatment. PARP inhibitors may also increase exogenous replication stress and thereby increase sensitivity to inhibitors of ataxia telangiectas...

Descripción completa

Detalles Bibliográficos
Autores principales: Ring, Alistair, Kilburn, Lucy S., Pearson, Alex, Moretti, Laura, Afshari-Mehr, Angelica, Wardley, Andrew M., Gurel, Bora, Macpherson, Iain R., Riisnaes, Ruth, Baird, Richard D., Martin, Sue, Roylance, Rebecca, Johnson, Hannah, Ferreira, Ana, Winter, Matthew C., Dunne, Kathryn, Copson, Ellen, Hickish, Tamas, Burcombe, Russell, Randle, Kat, Serra, Violeta, Llop-Guevara, Alba, Bliss, Judith M., Turner, Nicolas C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690092/
https://www.ncbi.nlm.nih.gov/pubmed/37773077
http://dx.doi.org/10.1158/1078-0432.CCR-23-1696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690092/
https://www.ncbi.nlm.nih.gov/pubmed/37773077
http://dx.doi.org/10.1158/1078-0432.CCR-23-1696

Ejemplares similares